Neural Noise- Local field potential (LFP) surveys can guide deep brain stimulation programming in Parkinson’s disease 1.
- A clinical-neurophysiological longitudinal study in Nature informs closed-loop and biomarker-guided stimulation 1. 1
Weekly enrichment (2026-07-20)
- The source study (npj Parkinson’s Disease, 2025 clinical-neurophysiological longitudinal study) enrolled 19 PD patients (9 women, age 55.8 ± 7.5 years) with bilateral sensing-enabled DBS — 12 STN and 7 GPi — all implanted with the Medtronic Percept PC neurostimulator and segmented quadripolar leads (model B33005, 0.5 mm intercontact spacing).2
- LFPs were captured with the BrainSense Survey feature (sampled at 250 Hz for ≈40 s, with stimulation off ≥2 min), band-pass filtered 5–98 Hz, and beta peaks (13–30 Hz) extracted via Welch’s method (1 s windows, 50% overlap) in MATLAB.2
- Three beta-amplitude contact-selection methods were compared against clinical monopolar review: Broad-Bipolar (1–3 vs 0–2), Narrow-Bipolar (2–3 vs 0–1), and Segment-Bipolar; Narrow-Bipolar had the strongest correlation and agreement with clinical programming and performed equally in STN and GPi.2
- Narrow-Bipolar was the most temporally stable, matching the chronically used contact level in 88.8% (32/36 hemispheres) between initial programming and follow-up (≥6 months), versus 75% (27/36) for clinical selection itself; beta peak amplitude, frequency, and power did not change significantly over that interval.2
- Because the method indicates whether the beta source lies more dorsal or ventral on the lead, it can roughly halve the number of contact levels that need clinical testing, reducing programming time and follow-up burden in resource-limited centers.2
- Subthalamic beta-band (13–30 Hz) hypersynchrony correlates with rigidity and bradykinesia and is suppressed by levodopa and DBS, which is why it has become the leading biomarker for both contact selection and adaptive closed-loop DBS.23
- A prior randomized, blinded three-arm crossover pilot trial (8 STN-DBS patients evaluated 3 months post-op) found beta-guided and imaging-guided programming produced clinical efficacy similar to conventional clinical programming but took significantly less time (p<0.001).4
- In the ADAPT-PD sensing dataset, an LFP beta peak meeting inclusion criteria was present in 84% (57/68) of participants, and beta is reported in roughly 95% of patients in the off-medication state, supporting broad applicability of beta-guided and closed-loop programming.5
- The contact exhibiting the highest beta activity generally also shows the largest therapeutic window and best clinical outcome, and stimulation-induced beta suppression tracks motor improvement, underpinning these data-driven contact-selection strategies.3